Tension  ||| S:0 E:8 ||| NNP
Type  ||| S:8 E:13 ||| NNP
Headache  ||| S:13 E:22 ||| NNP
Tension  ||| S:22 E:30 ||| NNP
type  ||| S:30 E:35 ||| NN
headache  ||| S:35 E:44 ||| NN
( ||| S:44 E:45 ||| -LRB-
TTH ||| S:45 E:48 ||| NNP
)  ||| S:48 E:50 ||| -RRB-
is  ||| S:50 E:53 ||| VBZ
the  ||| S:53 E:57 ||| DT
most  ||| S:57 E:62 ||| RBS
common  ||| S:62 E:69 ||| JJ
headache  ||| S:69 E:78 ||| NN
and  ||| S:78 E:82 ||| CC
it  ||| S:82 E:85 ||| PRP
has  ||| S:85 E:89 ||| VBZ
been  ||| S:89 E:94 ||| VBN
discussed  ||| S:94 E:104 ||| VBN
for  ||| S:104 E:108 ||| IN
years  ||| S:108 E:114 ||| NNS
without  ||| S:114 E:122 ||| IN
reaching  ||| S:122 E:131 ||| VBG
consensus  ||| S:131 E:141 ||| NN
on  ||| S:141 E:144 ||| IN
its  ||| S:144 E:148 ||| PRP$
pathophysiology ||| S:148 E:163 ||| NN
,  ||| S:163 E:165 ||| ,
or  ||| S:165 E:168 ||| CC
proper  ||| S:168 E:175 ||| JJ
rationale  ||| S:175 E:185 ||| NN
management ||| S:185 E:195 ||| NN
.  ||| S:195 E:197 ||| .
This  ||| S:197 E:202 ||| DT
primary  ||| S:202 E:210 ||| JJ
headache  ||| S:210 E:219 ||| NN
remains  ||| S:219 E:227 ||| VBZ
a  ||| S:227 E:229 ||| DT
challenge  ||| S:229 E:239 ||| NN
into  ||| S:239 E:244 ||| IN
its  ||| S:244 E:248 ||| PRP$
management  ||| S:248 E:259 ||| NN
for  ||| S:259 E:263 ||| IN
clinicians ||| S:263 E:273 ||| NN
.  ||| S:273 E:275 ||| .
This  ||| S:275 E:280 ||| DT
review  ||| S:280 E:287 ||| NN
aims  ||| S:287 E:292 ||| VBZ
to  ||| S:292 E:295 ||| TO
provide  ||| S:295 E:303 ||| VB
an  ||| S:303 E:306 ||| DT
updated  ||| S:306 E:314 ||| NN
and  ||| S:314 E:318 ||| CC
critical  ||| S:318 E:327 ||| JJ
discussion  ||| S:327 E:338 ||| NN
on  ||| S:338 E:341 ||| IN
what  ||| S:341 E:346 ||| WP
is  ||| S:346 E:349 ||| VBZ
currently  ||| S:349 E:359 ||| RB
known  ||| S:359 E:365 ||| VBN
and  ||| S:365 E:369 ||| CC
supported  ||| S:369 E:379 ||| VBN
by  ||| S:379 E:382 ||| IN
scientific  ||| S:382 E:393 ||| JJ
evidence  ||| S:393 E:402 ||| NN
about  ||| S:402 E:408 ||| IN
TTH  ||| S:408 E:412 ||| NNP
and  ||| S:412 E:416 ||| CC
which  ||| S:416 E:422 ||| WDT
gaps  ||| S:422 E:427 ||| VBP
there  ||| S:427 E:433 ||| RB
still  ||| S:433 E:439 ||| RB
may  ||| S:439 E:443 ||| MD
be  ||| S:443 E:446 ||| VB
in  ||| S:446 E:449 ||| IN
our  ||| S:449 E:453 ||| PRP$
understanding  ||| S:453 E:467 ||| NN
of  ||| S:467 E:470 ||| IN
this  ||| S:470 E:475 ||| DT
condition ||| S:475 E:484 ||| NN
.  ||| S:484 E:486 ||| .
Clinical  ||| S:486 E:495 ||| JJ
features  ||| S:495 E:504 ||| NNS
of  ||| S:504 E:507 ||| IN
TTH  ||| S:507 E:511 ||| NNP
resemble  ||| S:511 E:520 ||| VBP
common  ||| S:520 E:527 ||| JJ
manifestations  ||| S:527 E:542 ||| NNS
of  ||| S:542 E:545 ||| IN
muscle  ||| S:545 E:552 ||| NN
referred  ||| S:552 E:561 ||| VBD
pain ||| S:561 E:565 ||| NN
.  ||| S:565 E:567 ||| .
Episodic  ||| S:567 E:576 ||| NNP
TTH  ||| S:576 E:580 ||| NNP
may  ||| S:580 E:584 ||| MD
evolve  ||| S:584 E:591 ||| VB
into  ||| S:591 E:596 ||| IN
the  ||| S:596 E:600 ||| DT
chronic  ||| S:600 E:608 ||| JJ
form  ||| S:608 E:613 ||| NN
by  ||| S:613 E:616 ||| IN
different  ||| S:616 E:626 ||| JJ
aspects  ||| S:626 E:634 ||| NNS
and  ||| S:634 E:638 ||| CC
several  ||| S:638 E:646 ||| JJ
triggers  ||| S:646 E:655 ||| NN
may  ||| S:655 E:659 ||| MD
be  ||| S:659 E:662 ||| VB
involved  ||| S:662 E:671 ||| VBN
at  ||| S:671 E:674 ||| IN
the  ||| S:674 E:678 ||| DT
same  ||| S:678 E:683 ||| JJ
time ||| S:683 E:687 ||| NN
.  ||| S:687 E:689 ||| .
Both  ||| S:689 E:694 ||| DT
peripheral  ||| S:694 E:705 ||| JJ
and  ||| S:705 E:709 ||| CC
central  ||| S:709 E:717 ||| JJ
sensitization  ||| S:717 E:731 ||| JJ
mechanisms  ||| S:731 E:742 ||| NNS
seem  ||| S:742 E:747 ||| VBP
to  ||| S:747 E:750 ||| TO
be  ||| S:750 E:753 ||| VB
clearly  ||| S:753 E:761 ||| RB
involved  ||| S:761 E:770 ||| VBN
in  ||| S:770 E:773 ||| IN
this  ||| S:773 E:778 ||| DT
process ||| S:778 E:785 ||| NN
.  ||| S:785 E:787 ||| .
Individuals  ||| S:787 E:799 ||| NNS
with  ||| S:799 E:804 ||| IN
episodic  ||| S:804 E:813 ||| JJ
TTH  ||| S:813 E:817 ||| NNP
exhibit  ||| S:817 E:825 ||| NN
higher  ||| S:825 E:832 ||| JJR
levels  ||| S:832 E:839 ||| NNS
of  ||| S:839 E:842 ||| IN
peripheral  ||| S:842 E:853 ||| JJ
excitability  ||| S:853 E:866 ||| NN
whereas  ||| S:866 E:874 ||| IN
chronic  ||| S:874 E:882 ||| JJ
TTH  ||| S:882 E:886 ||| NNP
clearly  ||| S:886 E:894 ||| RB
show  ||| S:894 E:899 ||| VB
central  ||| S:899 E:907 ||| JJ
sensitization  ||| S:907 E:921 ||| JJ
manifestations ||| S:921 E:935 ||| NNS
.  ||| S:935 E:937 ||| .
The  ||| S:937 E:941 ||| DT
role  ||| S:941 E:946 ||| NN
of  ||| S:946 E:949 ||| IN
associated  ||| S:949 E:960 ||| JJ
muscle  ||| S:960 E:967 ||| NN
hyperalgesia  ||| S:967 E:980 ||| NN
seems  ||| S:980 E:986 ||| VBZ
to  ||| S:986 E:989 ||| TO
be  ||| S:989 E:992 ||| VB
important  ||| S:992 E:1002 ||| JJ
factors  ||| S:1002 E:1010 ||| NNS
in  ||| S:1010 E:1013 ||| IN
TTH ||| S:1013 E:1016 ||| NNP
.  ||| S:1016 E:1018 ||| .
Therapeutic  ||| S:1018 E:1030 ||| JJ
management  ||| S:1030 E:1041 ||| NN
of  ||| S:1041 E:1044 ||| IN
individuals  ||| S:1044 E:1056 ||| NNS
with  ||| S:1056 E:1061 ||| IN
TTH  ||| S:1061 E:1065 ||| NNP
should  ||| S:1065 E:1072 ||| MD
be  ||| S:1072 E:1075 ||| VB
multimodal  ||| S:1075 E:1086 ||| VBN
including  ||| S:1086 E:1096 ||| VBG
appropriate  ||| S:1096 E:1108 ||| JJ
use  ||| S:1108 E:1112 ||| NN
of  ||| S:1112 E:1115 ||| IN
pharmacological  ||| S:1115 E:1131 ||| NN
and  ||| S:1131 E:1135 ||| CC
non-pharmacological  ||| S:1135 E:1155 ||| JJ
interventions  ||| S:1155 E:1169 ||| NNS
to  ||| S:1169 E:1172 ||| TO
reduce  ||| S:1172 E:1179 ||| VB
the  ||| S:1179 E:1183 ||| DT
nociceptive  ||| S:1183 E:1195 ||| JJ
peripheral  ||| S:1195 E:1206 ||| JJ
drive  ||| S:1206 E:1212 ||| NN
to  ||| S:1212 E:1215 ||| TO
the  ||| S:1215 E:1219 ||| DT
central  ||| S:1219 E:1227 ||| JJ
nervous  ||| S:1227 E:1235 ||| JJ
system ||| S:1235 E:1241 ||| NN
.  ||| S:1241 E:1243 ||| .
If  ||| S:1243 E:1246 ||| IN
properly  ||| S:1246 E:1255 ||| RB
applied ||| S:1255 E:1262 ||| VBN
,  ||| S:1262 E:1264 ||| ,
treatment  ||| S:1264 E:1274 ||| NN
may  ||| S:1274 E:1278 ||| MD
not  ||| S:1278 E:1282 ||| RB
only  ||| S:1282 E:1287 ||| RB
reduce  ||| S:1287 E:1294 ||| VB
the  ||| S:1294 E:1298 ||| DT
number  ||| S:1298 E:1305 ||| NN
of  ||| S:1305 E:1308 ||| IN
TTH  ||| S:1308 E:1312 ||| NNP
attacks  ||| S:1312 E:1320 ||| NNS
but  ||| S:1320 E:1324 ||| CC
may  ||| S:1324 E:1328 ||| MD
also  ||| S:1328 E:1333 ||| RB
prevent  ||| S:1333 E:1341 ||| VB
or  ||| S:1341 E:1344 ||| CC
delay  ||| S:1344 E:1350 ||| VB
the  ||| S:1350 E:1354 ||| DT
transition  ||| S:1354 E:1365 ||| NN
from  ||| S:1365 E:1370 ||| IN
episodic  ||| S:1370 E:1379 ||| JJ
to  ||| S:1379 E:1382 ||| TO
chronic  ||| S:1382 E:1390 ||| VB
TTH ||| S:1390 E:1393 ||| NNP
.  ||| S:1393 E:1395 ||| .
Scientific  ||| S:1395 E:1406 ||| JJ
evidence  ||| S:1406 E:1415 ||| NN
of  ||| S:1415 E:1418 ||| IN
pharmacological  ||| S:1418 E:1434 ||| NN
and  ||| S:1434 E:1438 ||| CC
non-pharmacological  ||| S:1438 E:1458 ||| JJ
treatment  ||| S:1458 E:1468 ||| NN
is  ||| S:1468 E:1471 ||| VBZ
discussed  ||| S:1471 E:1481 ||| VBN
in  ||| S:1481 E:1484 ||| IN
this  ||| S:1484 E:1489 ||| DT
review ||| S:1489 E:1495 ||| NN
.  ||| S:1495 E:1497 ||| .
